Understanding how chemotherapy affects immune response in lung cancer treatment
Identifying and targeting a novel mechanism of chemotherapy-induced immunotherapeutic resistance in non-small cell lung cancer
['FUNDING_R01'] · UNIVERSITY OF LOUISVILLE · NIH-11055285
This study is looking at how the chemotherapy drug cisplatin affects the immune system in people with non-small cell lung cancer, to find out how it might make immunotherapy less effective, and to discover better ways to boost treatment options for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF LOUISVILLE (nih funded) |
| Locations | 1 site (LOUISVILLE, UNITED STATES) |
| Trial ID | NIH-11055285 on ClinicalTrials.gov |
What this research studies
This research investigates the effects of cisplatin, a common chemotherapy drug, on the immune response in patients with non-small cell lung cancer (NSCLC). It aims to understand how cisplatin may create an environment that suppresses the effectiveness of immunotherapy, specifically targeting the PD-1 pathway. By studying the interactions between chemotherapy and immune cells, the research seeks to identify new strategies to enhance the efficacy of immunotherapy in lung cancer patients. Patients may be involved in trials that explore these mechanisms and potential new treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are undergoing or considering chemotherapy treatment.
Not a fit: Patients with other types of lung cancer or those who are not receiving chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that enhance the effectiveness of immunotherapy for lung cancer patients.
How similar studies have performed: Previous research has shown that understanding the tumor microenvironment can lead to significant advancements in cancer treatment, suggesting potential success for this approach.
Where this research is happening
LOUISVILLE, UNITED STATES
- UNIVERSITY OF LOUISVILLE — LOUISVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YADDANAPUDI, KAVITHA — UNIVERSITY OF LOUISVILLE
- Study coordinator: YADDANAPUDI, KAVITHA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy